TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14618645

Group type: EXPERIMENTAL
Intervention: Budesonide or Nedocromil (anti-inflammatory therapy)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 41
Study: 10761282

Group type: EXPERIMENTAL
Intervention: Positive questioning group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Negative questioning group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (irrelevant issues)
Number of subjects: 120
Study: 8796410

Group type: EXPERIMENTAL
Intervention: i.v. bolus of 1 g/kg of 25% albumin over 4 h, repeated after 24 and 48 h
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Continuous 24-h infusion of 1 g/kg of 25% albumin throughout the 60-h study period
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 37
Study: 1320259

Group type: EXPERIMENTAL
Intervention: ORG 2766 (20 mg, 4 capsules daily for six weeks)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo (4 capsules daily for six weeks)
Number of subjects: 3
Study: 3881948

Group type: EXPERIMENTAL
Intervention: Aztreonam 0.5 to 1 g twice daily
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Aztreonam 1 g three times daily
Number of subjects: 159

Group type: COMPARATOR
Intervention: Cefamandole 1 g three times daily
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Aztreonam 1 to 6 g per day for eight days
Number of subjects: 159
Study: 30964750

Group type: EXPERIMENTAL
Intervention: Strengths-based case management over 6 months
Number of subjects: 349

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 349
Study: 30477732

Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 139

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 139
Study: 27456983

Group type: EXPERIMENTAL
Intervention: Protease inhibitor monotherapy (80% darunavir, 14% lopinavir, 6% other)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Ongoing triple therapy
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Protease inhibitor monotherapy
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Roche TaqMan‐2 assay
Number of subjects: 290
Study: 24708623

Group type: EXPERIMENTAL
Intervention: Tailored implementation strategy for enhancing adherence to COPD management guidelines (including brief anti-smoking advice, dyspnea assessment, care checklist utilization, and demonstration of correct inhaler use)
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Usual care provided by control practices
Number of subjects: 1440
Study: 22310542

Group type: EXPERIMENTAL
Intervention: Lopinavir plus azithothymidine/3TC
Number of subjects: 43

Group type: COMPARATOR
Intervention: Efavirenz plus azithothymidine/3TC
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Geno2pheno([clinical]) FPR analysis
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Transmitted drug resistance mutations
Number of subjects: 43
Study: 20178875

Group type: EXPERIMENTAL
Intervention: Western medicine (WM) - Terazosin Hydrochloride Hytrin (THH)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Traditional Chinese medicine (TCM) - herbal Saxifrage tablet (HST)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both treatments (WM and TCM)
Number of subjects: 61
Study: 16636816

Group type: EXPERIMENTAL
Intervention: Back care + physical activity promotion program
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Back care program
Number of subjects: 555

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 555
Study: 16255016

Group type: EXPERIMENTAL
Intervention: IA yttrium‐90 plus glucocorticoids (GCs)
Number of subjects: 97

Group type: COMPARATOR
Intervention: IA placebo yttrium plus glucocorticoids (GCs)
Number of subjects: 97
Study: 12131599

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 15251662

Group type: EXPERIMENTAL
Intervention: Levothyroxine (1.5 to 2.0 mg/kg of body weight daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 7734104

Group type: EXPERIMENTAL
Intervention: 5 mg ICR
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: 10 mg ICR
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: 15 mg ICR
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: 20 mg ICR
Number of subjects: 384

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study: 2390689

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 5 FU
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intraperitoneal administration of 5 FU
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Measurement of fluoro‐beta‐alanine (FBAL)
Number of subjects: 4
Study: 396658

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31987536

Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus nanoparticle gel applied by phonophoresis (PP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ultrasound therapy (UT)
Number of subjects: 40
Study: 31469816

Group type: COMPARATOR
Intervention: Nivolumab plus ipilimumab (first-line treatment)
Number of subjects: 847

Group type: COMPARATOR
Intervention: Nivolumab (second-line treatment)
Number of subjects: 847
Study: 28492860

Group type: EXPERIMENTAL
Intervention: Aflibercept, 2.0 mg
Number of subjects: 362

Group type: COMPARATOR
Intervention: Bevacizumab, 1.25 mg
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment prior to study participation
Number of subjects: 362
Study: 25931733

Group type: EXPERIMENTAL
Intervention: Upper thoracic manipulation after cervical stability training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cervical stability training alone
Number of subjects: 30
Study: 24332416

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: True bifurcation lesion (TBL)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Multiple stents
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Culotte stenting
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: SYNTAX scores
Number of subjects: 607
Study: 22717102

Group type: EXPERIMENTAL
Intervention: OPRM1 genotype (G allele presence) among non-Hispanic whites
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: OPRM1 genotype (G allele presence) among Hispanics
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: OPRM1 genotype (G allele presence) among African Americans
Number of subjects: 247
Study: 19244157

Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity
Number of subjects: 102

Group type: COMPARATOR
Intervention: Health education (Control)
Number of subjects: 102
Study: 17132678

Group type: EXPERIMENTAL
Intervention: Fortified milk
Number of subjects: 633

Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 633
Study: 15488105

Group type: EXPERIMENTAL
Intervention: Harm reduction approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efficacious interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized treatment efficacy trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual difference variables
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdisciplinary research
Number of subjects: 0
Study: 11241122

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 1326
Study: 9763798

Group type: EXPERIMENTAL
Intervention: Running during the fourth stage of the Bruce treadmill protocol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Walking during the fourth stage of the Bruce treadmill protocol
Number of subjects: 27
Study: 7812072

Group type: EXPERIMENTAL
Intervention: 800 mg/day Calcium supplements (two different forms)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Calcium supplements (in fractured patients)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 2338120

Group type: EXPERIMENTAL
Intervention: Diclofenac hydroxyethylpyrrolidine (DIEP) 2 X 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diclofenac sodium 2 X 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of AUC values
Number of subjects: 0
Study: 879220

Group type: EXPERIMENTAL
Intervention: Deceleration Delay Index (DDI)
Number of subjects: 106
Study: 31126971

Group type: EXPERIMENTAL
Intervention: Family-based intervention 1
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Family-based intervention 2
Number of subjects: 360

Group type: COMPARATOR
Intervention: Education-only control group
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Family-based interventions
Number of subjects: 360
Study: 28975429

Group type: EXPERIMENTAL
Intervention: Intra-oral cooling device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ice chips
Number of subjects: 20
Study: 24801607

Group type: EXPERIMENTAL
Intervention: Cognitive activity (CA) strategy training
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control nonspecific educational program
Number of subjects: 160
Study: 23639862

Group type: EXPERIMENTAL
Intervention: Bowman Birk Inhibitor Concentrate (BBIC)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 20693809

Group type: EXPERIMENTAL
Intervention: Standard therapy + infliximab
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 33
Study: 19805692

Group type: EXPERIMENTAL
Intervention: Oral satraplatin (80 mg/m² on days 1 to 5 of a 35-day cycle) and prednisone (5 mg twice daily)
Number of subjects: 950

Group type: COMPARATOR
Intervention: Placebo and prednisone (5 mg twice daily)
Number of subjects: 950
Study: 16715948

Group type: EXPERIMENTAL
Intervention: 90Y-citrate
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 90Y-silicate
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 186Re-sulfide
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study: 15875093

Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/daily)
Number of subjects: 1802

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1802
Study: 12533364

Group type: EXPERIMENTAL
Intervention: Dynamic sliding loop suture technique
Number of subjects: 37

Group type: COMPARATOR
Intervention: Traditional suture technique
Number of subjects: 37
Study: 10192656

Group type: EXPERIMENTAL
Intervention: Oestrogen replacement therapy (2 mg of 17-beta-oestradiol orally for 3 months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 7766744

Group type: EXPERIMENTAL
Intervention: Effervescent ranitidine (300 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Regular ranitidine (300 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Effervescent cimetidine (800 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Regular cimetidine (800 mg)
Number of subjects: 12
Study: 2148702

Group type: EXPERIMENTAL
Intervention: Peak flow self management plan
Number of subjects: 115

Group type: COMPARATOR
Intervention: Symptoms only self management plan
Number of subjects: 115
Study: 6108264

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 12480822

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of [3H]L-arginine (300 nCi/min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Myocardial samples from patients with CHF
Number of subjects: 7
Study: 31342375

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 201

Group type: COMPARATOR
Intervention: High-quality websites
Number of subjects: 201
Study: 29882070

Group type: EXPERIMENTAL
Intervention: FOLFIRI with cetuximab
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: FOLFIRI with bevacizumab
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Mean attenuation ≥61.62 HU
Number of subjects: 592
Study: 26830643

Group type: EXPERIMENTAL
Intervention: Thoracic epidural catheter threading distance of 7 cm
Number of subjects: 120

Group type: COMPARATOR
Intervention: Combined thoracic epidural catheter threading distances of 3 cm and 5 cm
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups (3CM, 5CM, 7CM)
Number of subjects: 120
Study: 23773323

Group type: EXPERIMENTAL
Intervention: Predominant delusional themes at baseline
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Follow-up assessments at years 1, 2, and 5
Number of subjects: 411
Study: 22702369

Group type: EXPERIMENTAL
Intervention: Modified pulmonary vein isolation (PVI)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional pulmonary vein isolation (PVI)
Number of subjects: 126
Study: 20478070

Group type: EXPERIMENTAL
Intervention: Newhints intervention (routine home visits providing essential newborn care interventions)
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15000
Study: 17566093

Group type: EXPERIMENTAL
Intervention: Flutamide 125 mg
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Flutamide 375 mg
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 16139123

Group type: EXPERIMENTAL
Intervention: Losartan with aspirin (n = 1,004)
Number of subjects: 9193

Group type: COMPARATOR
Intervention: Atenolol with aspirin (n = 966)
Number of subjects: 9193

Group type: EXPERIMENTAL
Intervention: Losartan with aspirin
Number of subjects: 9193

Group type: COMPARATOR
Intervention: Atenolol with aspirin
Number of subjects: 9193
Study: 12177584

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 150
Study: 10551346

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (C)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo beverage (P)
Number of subjects: 15
Study: 7844608

Group type: COMPARATOR
Intervention: HFX RT with 1.2 Gy twice daily to a total dose of 64.8 Gy (group I)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: HFX RT with CHT (100 mg of carboplatin on days 1 and 2 and 100 mg of etoposide on days 1 to 3 of each week during RT course) (group II)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: HFX RT with CHT (200 mg of carboplatin on days 1 and 2 and 100 mg of etoposide on days 1 to 5 of the first, third, and fifth weeks of RT course) (group III)
Number of subjects: 169
Study: 2189903

Group type: EXPERIMENTAL
Intervention: Nilvadipine 6 mg tid
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Nilvadipine 8 mg tid
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Nilvadipine 10 mg tid
Number of subjects: 84

Group type: COMPARATOR
Intervention: Nilvadipine
Number of subjects: 84
Study: 442709

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Caffeine-free coffee
Number of subjects: 12
Study: 31196026

Group type: EXPERIMENTAL
Intervention: Combined telephone and SMS intervention
Number of subjects: 750

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 750
Study: 27529732

Group type: EXPERIMENTAL
Intervention: One-jaw surgery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Two-jaw surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Orthodontic camouflage treatment (OCT)
Number of subjects: 30
Study: 25546447

Group type: EXPERIMENTAL
Intervention: Hip flexor stretch (HFS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hip extensor stretch (HES)
Number of subjects: 15
Study: 24113783

Group type: EXPERIMENTAL
Intervention: Oral pazopanib 15 mg daily (patients with AMD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oral pazopanib up to 30 mg daily (healthy participants)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rescue therapy (for patients with AMD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CFH Y402H T allele ('low risk' for AMD, n = 6)
Number of subjects: 15
Study: 21734019

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 0
Study: 18653310

Group type: EXPERIMENTAL
Intervention: Group cognitive behavior therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual cognitive behavior therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Educational/supportive psychotherapy (control)
Number of subjects: 0
Study: 17101568

Group type: EXPERIMENTAL
Intervention: EndoCinch plication technique
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 46
Study: 17016954

Group type: EXPERIMENTAL
Intervention: Fortified dietary supplement (25 g per school day for children; two 25-g sachets per day for pregnant women)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fortified dietary supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonfortified supplement
Number of subjects: 0
Study: 11106884

Group type: EXPERIMENTAL
Intervention: Patients with more hospitalizations and emergency room visits in the prior 6 months
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: Patients with higher blood urea nitrogen
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: Patients with lower mental health function
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: Patients with a diagnosis of COPD
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: Patients with increased satisfaction with access to emergency care
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: Overall population of 1378 patients
Number of subjects: 1378
Study: 8723804

Group type: EXPERIMENTAL
Intervention: Intratracheal instillation of large doses of bovine and porcine lung-derived surfactant preparations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 1677276

Group type: EXPERIMENTAL
Intervention: Electromyographic feedback training with contingent tone based on oral-lingual movements above a yoked threshold.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Noncontingent feedback tones generated randomly.
Number of subjects: 20
Study: 6129933

Group type: EXPERIMENTAL
Intervention: Almitrine (1 mg/kg intravenously)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Solvent (placebo)
Number of subjects: 7
Study: 31471504

Group type: EXPERIMENTAL
Intervention: BMI ≥30 kg/m2
Number of subjects: 120607

Group type: EXPERIMENTAL
Intervention: Blood pressure ≥160/100 mm Hg
Number of subjects: 120607
Study: 29137107

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 92
Study: 25968303

Group type: EXPERIMENTAL
Intervention: Formalised trauma tertiary survey (TTS) procedure
Number of subjects: 6380

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 6380
Study: 22552048

Group type: EXPERIMENTAL
Intervention: Docetaxel-based therapy (DP) following ketoconazole (KC)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Docetaxel-based therapy (DP) in KC-naive patients
Number of subjects: 220
Study: 21718804

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (650 mg daily, containing 250-280 mg DHA and at least 60 mg EPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olive oil supplementation (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (650 mg daily)
Number of subjects: 0
Study: 19918596

Group type: EXPERIMENTAL
Intervention: Zirconia frameworks cemented with glass-ionomer cement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control teeth (contralateral analogous teeth)
Number of subjects: 30
Study: 16738030

Group type: EXPERIMENTAL
Intervention: High levels of social identification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher identification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scenarios and recollection of personal experiences
Number of subjects: 0
Study: 15330959

Group type: EXPERIMENTAL
Intervention: OTFC (normal dose = 10-15 microg x kg(‐1) or low dose = 100 microg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: OTFC ND
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: OTFC
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: ondansetron (0.1 mg x kg(‐1) to 4 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 11182214

Group type: EXPERIMENTAL
Intervention: Regular diet and physical activity counselling based on the stages of change model
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 67
Study: 9709727

Group type: EXPERIMENTAL
Intervention: Participant modeling film
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nonrelevant film
Number of subjects: 42
Study: 8291726

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 26

Group type: COMPARATOR
Intervention: Compressed air (control)
Number of subjects: 26
Study: 2906898

Group type: EXPERIMENTAL
Intervention: Tienoxolol 150 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tienoxolol 300 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31314967

Group type: EXPERIMENTAL
Intervention: Intervention group received HIV testing and counseling, linkage to care, ART (started at a higher CD4 count), and increased access to male circumcision services.
Number of subjects: 12610

Group type: COMPARATOR
Intervention: Standard-care group received standard care without the enhanced intervention.
Number of subjects: 12610

Group type: EXPERIMENTAL
Intervention: Intervention group showed a significant increase in the percentage of HIV-positive participants with an HIV-1 RNA level of 400 copies per milliliter or less.
Number of subjects: 12610

Group type: COMPARATOR
Intervention: Standard-care group showed an increase in the percentage of HIV-positive participants with an HIV-1 RNA level of 400 copies per milliliter or less.
Number of subjects: 12610

Group type: EXPERIMENTAL
Intervention: Intervention group showed an increase in the percentage of men who underwent circumcision.
Number of subjects: 12610

Group type: COMPARATOR
Intervention: Standard-care group showed an increase in the percentage of men who underwent circumcision.
Number of subjects: 12610
Study: 28904070

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1063